OBJECTIVES: To describe disease course, severity level, and treatment of PsA patients in Canada. METHODS: Data were gathered from the Adelphi Real World 2015 Disease Specific Program. Rheumatologists (n=25) and dermatologists (n=5) completed patient record forms on consulting PsA patients. The same patients completed self-completion questionnaires voluntarily. Advanced therapy (AT) included patients receiving biologics and apremilast. RESULTS: Data were collected for 92 PsA patients; 53.3% were female, and mean age was 50.2 years. Patient-reported mean time since diagnosis was 2.45 years (n=66), although time from original symptom onset was 3.99 years (n=56). Advanced Therapy: